VlassesPHRotmenschHHSwansonBNMojaverianPFergusonRK. Low-dose Captopril. Its use in mild-to-moderate hypertension unresponsive to diuretic treatment. Arch Intern Med1982; 142: 1098–101.
12.
FergusonRKVlassesPHSwansonBNEffects of enalapril, a new converting enzyme inhibitor, in hypertension. Clin Pharmacol Ther1982; 32: 48–53.
13.
VlassesPHRotmenschHHSwansonBNComparative antihypertensive effects of enalapril maleate and hydrochlorothiazide, alone and in combination. J Clin Pharmacol1983; 23: 227–33.
14.
VlassesPHFergusonRKSmithJBRotmenschHHSwansonBN. Urinary excretion of prostacyclin and thromboxane A2 metabolites after ACE inhibition in hypertensive patients. Prostaglandins Leukotrienes Med1983; 11: 143–50.
15.
RotmenschHHVlassesPHSwansonBNAntihypertensive efficacy of once-daily MK-521: a new non-sulfhydryl angiotensin converting enzyme inhibitor. Am J Cardiol1984; 63: 116–9.
16.
VlassesPHConnerDPRotmenschHHDouble-blind comparison of Captopril and enalapril in mild-to-moderate hypertension. J Am Coll Cardiol1986; 7: 651–60.
17.
FedderILVlassesPHMojaverianPMorphine-induced miosis is related to plasma concentration in normal volunteers. J Pharm Sci1984; 73: 1496–7.
18.
VlassesPHRibeiroLGTRotmenschHHInitial evaluation of transdermal timolol: serum concentrations and betablockade. J Cardiovasc Pharmacol1985; 7: 245–50.
19.
GibaldiMPerrierD. Kinetics of pharmacologic response. In: GibaldiMPerrierD, eds. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982: 221–69.
20.
HolfordNHG. sheiner lb. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet1981; 6: 429–53.
21.
LevyG. Principles of clinical pharmacology: I. An introduction to the kinetics of pharmacologic effects. In: LembergerLReidenbergMM, eds. Proceedings of the 2nd World Conference on Clinical Pharmacology and Therapeutics. Bethesda, MD: American Society for Pharmacology and Experimental Therapeutics, 1984: 1–10.